Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers

The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer

(2018) Xiaoling Xu et al.   INTERNATIONAL JOURNAL OF CANCER

Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling

(2018) Xiaochao Zhang et al.   Cell Death & Disease

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

A novel combination strategy for effectively targeting cancer stem-like cells

(2017) Paul A Beavis et al.   IMMUNOLOGY AND CELL BIOLOGY

Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells

(2017) Hung-Chang Chen et al.   IMMUNOLOGY AND CELL BIOLOGY

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer

(2017) Xiaohui Zhang et al.   International Journal of Clinical Oncology

STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC

(2017) L.L. Bu et al.   JOURNAL OF DENTAL RESEARCH

Significance of immune checkpoint proteins in EGFR -mutant non-small cell lung cancer

(2017) Ross A. Soo et al.   LUNG CANCER

Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance

(2017) Ji Eun Choi et al.   ONCOLOGY REPORTS

The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3

(2017) T.J. Miller et al.   PATHOLOGY

YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells

(2017) Chun-Chia Cheng et al.   PLoS One

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models

(2017) Shujin Cui   MEDICAL SCIENCE MONITOR

Inhibitors of Cancer Stem Cells

(2016) María E. García-Rubiño et al.   Anti-Cancer Agents in Medicinal Chemistry

Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks inex vivoculture

(2016) Fanny Grillet et al.   GUT

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance

(2016) Katarzyna Miekus   ONCOLOGY REPORTS

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Pembrolizumab (Keytruda)

(2016) Gerry Kwok et al.   Human Vaccines & Immunotherapeutics

HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer

(2015) Paloma Ordóñez-Morán et al.   CANCER CELL

Immune responses to human cancer stem-like cells/cancer-initiating cells

(2015) Yoshihiko Hirohashi et al.   CANCER SCIENCE

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer

(2015) Thierry Jardé et al.   PLoS One

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway

(2014) Alexander Gross et al.   Targeted Oncology

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3

(2012) Woody Han et al.   MOLECULAR CARCINOGENESIS

Colorectal Cancer Stem Cells and Cell Death

(2011) Veronica Catalano et al.   Cancers

HER2 as a cancer stem-cell target

(2010) Rafael Roesler et al.   LANCET ONCOLOGY

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

(2009) N. A. Dallas et al.   CANCER RESEARCH

In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells

(2009) Erina Vlashi et al.   JNCI-Journal of the National Cancer Institute